Introduction to Elanco Animal Health Incorporated

Elanco Animal Health Incorporated, headquartered in Greenfield, Indiana, stands as a premier global entity dedicated to advancing animal health through innovative research, development, and delivery of veterinary pharmaceuticals, vaccines, feed additives, and diagnostics. With a rich heritage spanning over 70 years, Elanco has established itself as a trusted partner for veterinarians, livestock producers, and pet owners across more than 90 countries. The company's comprehensive portfolio addresses both companion animals and production animals, tackling critical health challenges such as disease prevention, parasitic control, and nutritional optimization. As a top-tier Healthcare company, Elanco earns recognition for its unwavering commitment to scientific excellence, regulatory compliance, and sustainable practices. Industry analysts consistently rank Elanco among the top animal health corporations globally, citing its robust pipeline, strategic acquisitions, and deep market penetration. Organizations ranging from family-owned farms to multinational agribusinesses rely on Elanco's solutions to ensure animal welfare, food safety, and economic viability. This reputation stems from decades of proven efficacy, ethical standards, and a corporate culture that prioritizes both innovation and compassion. In an industry where precision and trust are paramount, Elanco stands as a beacon of reliability and forward-thinking. The company’s annual revenue exceeds $4.4 billion, supported by a workforce of over 10,000 dedicated employees who embody the mission of 'Healthy Animals. Healthy Planet. Healthy People.' Elanco’s influence extends beyond product sales; it actively shapes veterinary education, public policy, and global health initiatives. For professionals seeking a career that blends scientific rigor with meaningful impact, Elanco offers an unparalleled platform to make a difference in the lives of animals and the communities that depend on them.

Company History and Business Evolution

The roots of Elanco Animal Health Incorporated stretch back to 1954, when Eli Lilly and Company established a division to focus on animal health products, primarily for poultry and livestock. Over the subsequent decades, the division expanded its offerings through internal innovation and strategic acquisitions, gradually becoming a standalone powerhouse within the veterinary space. A landmark moment occurred in 2018 when Eli Lilly spun off Elanco as an independent publicly traded company (NYSE: ELAN), allowing it to operate with greater agility and focus. Since then, Elanco has pursued an aggressive growth trajectory, highlighted by the 2020 acquisition of Bayer's animal health business for $7.6 billion—a transformative deal that bolstered its product portfolio with iconic brands like Advantage, Seresto, and Baytril. This acquisition not only expanded Elanco’s market share but also deepened its expertise in both companion and production animal segments. The company’s evolution mirrors broader trends in animal agriculture and pet care: increased demand for protein, rising pet ownership, and heightened awareness of zoonotic diseases. Elanco has continually adapted by investing in cutting-edge technologies such as genomics, digital diagnostics, and precision livestock farming. Its R&D pipeline remains robust, with dozens of active projects targeting unmet needs in areas like antimicrobial alternatives, pain management, and vaccine development. The company also pioneered the concept of 'One Health,' recognizing the interconnectedness of human, animal, and environmental health. Through collaborations with academic institutions, non-profits, and government agencies, Elanco has driven initiatives that reduce antibiotic use in agriculture, improve food safety, and combat climate change. Key milestones include the launch of the first FDA-approved canine cancer vaccine, the development of novel parasiticides that protect both animals and humans, and the establishment of the Elanco Foundation, which funds community-based animal health projects worldwide. As the company looks toward its next chapter, it continues to build on its heritage of innovation while embracing the challenges of a dynamic global market. The leadership team, under CEO Jeff Simmons, has articulated a clear vision: to become the world’s most trusted animal health company by delivering measurable outcomes that benefit animals, people, and the planet. This evolutionary journey is a testament to Elanco’s resilience, strategic foresight, and unwavering dedication to its core purpose.

Elanco Animal Health Incorporated at a Glance

• Headquarters: Greenfield, Indiana, United States
• Founded: 1954 (as division of Eli Lilly); spun off in 2018
• CEO: Jeff Simmons
• Revenue: Approximately $4.4 billion (2023)
• Employees: Over 10,000 worldwide
• Stock Symbol: NYSE: ELAN
• Global Presence: Operations in 90+ countries
• Product Lines: Pharmaceuticals, vaccines, feed additives, diagnostics, parasiticides
• Key Brands: Advantage, Seresto, Baytril, Rumensin, Tylan, Maxiban, Imrestor
• Market Segments: Companion animals (dogs, cats, horses), Production animals (cattle, swine, poultry, fish)
• R&D Investment: Over $400 million annually
• Regulatory Compliance: FDA, EMA, USDA, CFIA approved facilities
• Certifications: ISO 9001, ISO 14001, GMP, HACCP
• Awards: Forbes World's Best Employers, Best Places to Work (multiple years)
• Corporate Social Responsibility: Elanco Foundation, One Health initiatives, sustainability goals
• Digital Innovation: Precision livestock farming, telemedicine platforms, data analytics
• Competitors: Zoetis, Merck Animal Health, Boehringer Ingelheim, Ceva Santé Animale
• Patents: Active portfolio of over 1,000 granted patents
• Acquisitions: Bayer Animal Health (2020), Novartis Animal Health (2015), Ivy Animal Health (2022)
• Partnerships: Universities, veterinary associations, non-profits, government agencies

Mission, Vision, and Core Corporate Values

Elanco Animal Health Incorporated operates with a clearly articulated mission: 'Healthy Animals. Healthy Planet. Healthy People.' This three-pronged mission reflects the company’s holistic approach to animal health, recognizing that the well-being of animals is inextricably linked to environmental sustainability and human health. The vision extends beyond mere product sales; Elanco aspires to be the catalyst for a future where every animal receives optimal care, where food production is efficient and humane, and where zoonotic diseases are minimized. To realize this vision, the company upholds a set of core values that permeate every level of the organization. Integrity stands as the foundation—Elanco insists on ethical business practices, transparency in research, and compliance with all regulatory standards. Innovation drives the pursuit of breakthrough therapies and technologies that address unmet needs in veterinary medicine. Collaboration is essential, as Elanco actively partners with veterinarians, farmers, academics, and policymakers to co-create solutions. Accountability ensures that all stakeholders, from investors to animal owners, can trust the company’s commitments and performance. Passion for animal welfare and scientific excellence fuels the daily work of Elanco’s employees. These values are not just posted on walls; they are embedded in performance reviews, strategic planning, and community engagement. For example, the Elanco Foundation channels resources into veterinary education and rural development, while the company’s sustainability report details progress on reducing carbon emissions and water usage. In the workplace, these values translate into a culture of respect, diversity, and continuous learning. Elanco invests heavily in leadership development, mentoring programs, and employee well-being initiatives. The company also encourages employee resource groups that foster inclusion across gender, ethnicity, and backgrounds. By maintaining a strong ethical compass and a clear sense of purpose, Elanco attracts and retains talent that is not only skilled but also deeply committed to making a positive impact on the world.

Business Strategy and Future Roadmap

Elanco Animal Health Incorporated’s strategic roadmap is built on four pillars: Innovate to Lead, Portfolio Prioritization, Commercial Excellence, and Operational Efficiency. Under 'Innovate to Lead,' Elanco invests over $400 million annually in R&D, focusing on high-unmet-need areas such as antimicrobial alternatives, chronic disease management, and digital diagnostics. The company leverages its internal expertise and external partnerships to accelerate time-to-market for new products. 'Portfolio Prioritization' involves continuous evaluation of the product lineup, shedding legacy assets that no longer align with strategic goals while strengthening core franchises. For instance, Elanco has divested certain feed additive businesses to concentrate on higher-growth companion animal and specialty segments. 'Commercial Excellence' emphasizes customer-centric selling, digital marketing, and data-driven insights to optimize sales force effectiveness. Elanco has deployed advanced CRM systems and predictive analytics to tailor offerings to veterinarians and producers. 'Operational Efficiency' targets cost reductions through supply chain optimization, manufacturing automation, and procurement consolidation. The company aims to achieve $300 million in annual savings by 2025. Looking ahead, Elanco’s future roadmap includes aggressive expansion in emerging markets like Brazil, China, and India, where rising disposable incomes and protein consumption drive demand for animal health products. Additionally, Elanco plans to deepen its footprint in the pet wellness sector, offering not just treatments but preventive care packages, nutraceuticals, and telemedicine consultations. The company is also investing in precision livestock technologies—sensors, IoT devices, and AI-driven analytics—that enable farmers to monitor health, nutrition, and environmental conditions in real time. Sustainability is another key pillar; Elanco has committed to achieving carbon neutrality by 2040 and reducing water usage by 50% across its operations. Collaborations with non-profits, such as the World Wildlife Fund, help the company address environmental challenges at scale. In the regulatory arena, Elanco actively advocates for science-based policies that promote responsible antibiotic use and food safety. The company’s strategic agility was evident during the COVID-19 pandemic, when it quickly repurposed manufacturing lines to produce hand sanitizers and supported food supply chains disrupted by lockdowns. With a strong balance sheet and a clear sense of direction, Elanco is well-positioned to navigate market volatility and seize emerging opportunities.

Products, Technologies, and Services

Elanco Animal Health Incorporated offers an extensive array of products and services that span the entire spectrum of animal health needs. In the companion animal segment, the company’s flagship brands include Advantage (flea and tick control), Seresto (long-lasting collars), Baytril (antibiotics), and Imrestor (immune support). The portfolio also encompasses vaccines for rabies, distemper, and parvovirus; dermatological solutions; pain management drugs; and nutritional supplements. For production animals, Elanco provides feed additives like Rumensin (ionophore for cattle), Tylan (antibiotic for swine), Maxiban (coccidiostat for poultry), and a range of vaccines for respiratory and reproductive diseases. The company’s diagnostics division offers rapid tests for diseases such as bovine viral diarrhea virus (BVDV) and porcine reproductive and respiratory syndrome (PRRS). Beyond traditional pharmaceuticals, Elanco is pioneering digital technologies that transform veterinary practice. The Elanco Health Hub platform integrates electronic medical records, treatment protocols, and compliance alerts for veterinary clinics. FarmIQ is a data analytics tool that helps livestock farmers optimize nutrition, predict disease outbreaks, and track animal weight gain. Elanco also invests in telemedicine solutions that connect pet owners with licensed veterinarians remotely, expanding access to care. In the realm of biologics, the company’s R&D pipeline includes monoclonal antibodies for chronic pain, recombinant vaccines for emerging pathogens, and probiotics that enhance gut health. Elanco’s manufacturing capabilities are world-class, with FDA, EMA, and USDA-approved facilities in the US, Europe, and Asia. The company adheres to stringent quality assurance protocols, ensuring that every batch meets rigorous safety and efficacy standards. Additionally, Elanco offers customized services such as pharmacovigilance, regulatory support, and technical training for veterinarians and animal health professionals. Through its Elanco Innovation Lab, the company incubates early-stage ideas from internal and external sources, fostering a culture of continuous improvement. This comprehensive suite of products and services underscores Elanco’s commitment to addressing the diverse needs of its customers, from the smallest veterinary practice to the largest agribusiness.

Industries and Markets Served

Elanco Animal Health Incorporated operates at the intersection of multiple industries, serving stakeholders across the animal health ecosystem. The primary markets include veterinary medicine, where products are used by small animal practitioners and specialists for diagnosis, treatment, and prevention of diseases in companion animals. The livestock industry represents a major segment—Elanco’s solutions are deployed by cattle ranchers, pig farmers, poultry producers, and aquaculture operations to enhance productivity, reduce mortality, and ensure food safety. The pet retail channel is another critical market, where Elanco brands are sold through e-commerce platforms, pet specialty stores, and mass retailers. Furthermore, Elanco serves the agricultural biotechnology sector by providing feed additives that improve feed conversion ratios and reduce methane emissions. The company also collaborates with pharmaceutical companies and biotechs on co-development and licensing agreements. In the public health arena, Elanco works with government agencies and NGOs to control zoonotic diseases like rabies, avian influenza, and African swine fever, which have significant implications for human health. The academic and research community benefits from Elanco’s grants, scholarships, and joint research initiatives. Additionally, Elanco engages with regulatory bodies such as the FDA, EMA, USDA, and CFIA to shape standards and guidelines. The company’s market reach extends to over 90 countries, with strongholds in North America, Europe, Latin America, and Asia-Pacific. In each region, Elanco tailors its approach based on local disease prevalence, farming practices, and regulatory environments. For example, in Southeast Asia, the focus is on improving aquaculture health; in sub-Saharan Africa, Elanco supports smallholder livestock farmers with affordable vaccines and training. The diversity of markets served reflects Elanco’s versatility and its understanding that animal health challenges are context-specific. By addressing the needs of such a wide array of industries, Elanco not only drives its own growth but also contributes to global food security, economic development, and public health.

Leadership and Management Philosophy

The leadership team at Elanco Animal Health Incorporated is composed of seasoned executives with deep experience in veterinary science, pharmaceuticals, and global business operations. Jeff Simmons, President and CEO, has been at the helm since the spin-off, guiding the company through a period of significant transformation. Under his leadership, Elanco has embraced a decentralized management model that empowers regional leaders to make decisions aligned with local market dynamics. The management philosophy centers on three principles: Purpose-Driven Leadership, Empowered Teams, and Data-Informed Decision Making. Purpose-driven leadership means that every strategic move is evaluated through the lens of the company’s mission, ensuring that short-term gains do not compromise long-term values. Empowered teams are encouraged to take ownership of their projects, with leaders acting as coaches rather than micromanagers. Data-informed decision making involves rigorous analytics to prioritize investments, measure outcomes, and pivot when necessary. Elanco’s corporate governance structure includes a board of directors with independent members representing diverse backgrounds—veterinary medicine, finance, sustainability, and international trade. The company also has a strong compliance culture, with a dedicated Chief Ethics and Compliance Officer who oversees training and auditing programs. Leadership development is a priority; Elanco offers internal courses, executive coaching, and cross-functional rotations to groom the next generation of leaders. The company’s annual employee satisfaction survey consistently scores high for transparency, trust, and work-life balance. Moreover, Elanco’s leadership is actively involved in industry associations such as the Animal Health Institute and the World Veterinary Association, influencing policy and advancing best practices. This management philosophy has earned Elanco recognition as one of Forbes’ World’s Best Employers and a top workplace in the pharmaceutical sector. By fostering a culture of integrity, innovation, and collaboration, Elanco attracts and retains high-caliber professionals who are committed to making a difference in animal health.

Corporate Events, Conferences, and Community Engagement

Elanco Animal Health Incorporated maintains an active calendar of corporate events and participates in major industry conferences to showcase innovations, network with stakeholders, and contribute to thought leadership. Annual events include the Elanco Global Health Summit, where internal teams and external experts discuss trends in animal health, sustainability, and digital transformation. The company also hosts Veterinary Symposia in multiple regions, providing continuing education credits for practitioners. Elanco is a prominent exhibitor at international trade shows such as the World Veterinary Congress, IPPE (International Production & Processing Expo), VetFest, and National Cattlemen’s Beef Association Conference. At these venues, Elanco showcases new products, shares clinical data, and facilitates workshops. Community engagement is a cornerstone of the company’s CSR efforts. The Elanco Foundation awards grants to non-profit organizations that promote animal welfare, veterinary education, and rural community development. Employees participate in annual volunteer days, such as the Elanco Day of Service, where teams around the world contribute to local shelters, farms, and clinics. The company’s One Health Initiative includes partnerships with the World Health Organization and the Food and Agriculture Organization to combat diseases at the human-animal-environment interface. Elanco also sponsors school outreach programs that teach children about responsible pet ownership and food safety. In the wake of natural disasters, Elanco mobilizes resources to provide emergency veterinary care and supplies. For instance, during hurricanes and wildfires, the company donates vaccines, feed supplements, and financial support to affected livestock and companion animal rescue efforts. The company’s sustainability report details progress on its Healthy Planet goals, including reducing greenhouse gas emissions, minimizing waste, and conserving water. By engaging in these events and initiatives, Elanco reinforces its reputation as a responsible corporate citizen deeply invested in the well-being of animals and communities.

Employees and Workplace Culture

Elanco Animal Health Incorporated prides itself on a workplace culture that values diversity, inclusion, and employee well-being. The company employs over 10,000 people across 90 countries, representing a wide range of cultures, backgrounds, and professional expertise. Elanco’s Diversity, Equity, and Inclusion (DE&I) initiatives are spearheaded by an executive-led council and include employee resource groups for women, ethnic minorities, LGBTQ+, and veterans. These groups organize mentoring programs, networking events, and awareness campaigns. The company also offers generous parental leave, flexible work arrangements, and mental health support through an employee assistance program. Learning and development are central to the employee experience; Elanco provides online courses, leadership training, tuition reimbursement, and access to conferences. The company’s performance management system emphasizes continuous feedback and goal alignment with the company’s values. Elanco’s compensation packages are competitive, including base salary, annual bonuses, stock options, and performance-based incentives. The workplace environment is described as collaborative and fast-paced, with cross-functional teams working on projects that span research, manufacturing, marketing, and sales. Employee satisfaction surveys reveal high scores for job pride and teamwork, with many employees citing the mission-driven nature of the work as a key motivator. The company also recognizes outstanding contributions through awards like the Elanco Innovation Award and CEO Spotlight Awards. In 2023, Elanco was named one of Forbes’ World’s Best Employers and received Great Place to Work certification in several countries. The company’s Greenfield headquarters features modern amenities, including on-site fitness centers, childcare facilities, and a cafeteria offering healthy options. Remote and hybrid work models have been adopted for roles that can be performed off-site, reflecting Elanco’s commitment to work-life balance. By investing in its people, Elanco ensures that it attracts and retains top talent, which in turn drives innovation and business success.

Job Details & Requirements for this Posting

Position: Senior Veterinary Research Scientist – Elanco Animal Health Incorporated
Location: Greenfield, Indiana (On-site)
Employment Type: Full-time
Reports to: Director, Veterinary Research & Development

Role Overview: We are seeking a highly skilled and motivated Senior Veterinary Research Scientist to join our R&D team. In this role, you will design and execute preclinical and clinical studies to evaluate the safety and efficacy of novel veterinary pharmaceutical candidates. You will collaborate with cross-functional teams including biologists, chemists, regulatory affairs, and statistical analysts to advance our pipeline. The ideal candidate will have a deep understanding of animal physiology, pharmacology, and study design, as well as a passion for improving animal health.

Key Responsibilities:

• Develop study protocols, timelines, and budgets for GLP and non-GLP studies in target species (companion animals, livestock).
• Oversee study conduct at contract research organizations (CROs) and internal facilities, ensuring compliance with animal welfare regulations.
• Analyze and interpret data, prepare reports, and present findings to internal and external stakeholders.
• Contribute to regulatory submissions (FDA, EMA, USDA) and respond to agency inquiries.
• Mentor junior scientists and technicians, fostering a culture of scientific excellence.
• Stay current with emerging scientific literature and industry trends to inform research strategy.

Qualifications:

• DVM or PhD in Veterinary Science, Pharmacology, or related field; PhD with DVM preferred.
• Minimum 5 years of experience in veterinary drug development, preferably in the animal health industry.
• Strong knowledge of ICH guidelines, GLP/GCP, and animal welfare regulations.
• Proven track record of leading studies and delivering results in a fast-paced environment.
• Excellent written and verbal communication skills; ability to work in cross-functional teams.
• Experience with statistical software (e.g., SAS, R) and data visualization tools.
• Eligibility to work in the United States.

Why Join Elanco Animal Health Incorporated?

• Be part of a mission-driven organization that directly impacts animal and human health.
• Access to cutting-edge research facilities and a robust pipeline of innovative projects.
• Competitive compensation and benefits package, including health insurance, retirement plans, and paid time off.
• Opportunities for professional growth through training programs, conferences, and collaboration with global experts.
• A supportive, inclusive culture that values scientific curiosity and work-life balance.

Customer Reviews and Industry Reputation

Elanco Animal Health Incorporated enjoys a strong reputation across customer review platforms, with consistently positive feedback from veterinarians, farmers, pet owners, and employees. Below is an exhaustive analysis of reviews from key sources.

Glassdoor

On Glassdoor, Elanco holds an overall rating of 4.1 out of 5 stars based on thousands of reviews. Employees frequently praise the company’s mission-driven culture, innovative spirit, and supportive management. Many reviewers highlight the collaborative environment, where cross-functional teams work seamlessly to deliver results. The compensation and benefits package is rated highly, with mentions of competitive salaries and comprehensive health coverage. Some reviews note challenges related to organizational changes from acquisitions, but overall sentiment remains positive. Common pros include: “Great work-life balance,” “Passionate colleagues,” and “Real impact on animal health.” Cons occasionally cited: “Bureaucracy in larger departments” and “Variable pace of decision-making.”

Indeed

Indeed reviews echo Glassdoor sentiments, with an average rating of 3.9 stars. Employees appreciate the global scope of the work and the opportunity to contribute to meaningful projects. The company’s commitment to DE&I is frequently mentioned as a strength. Areas for improvement include occasional communication breakdowns between departments. Many reviews emphasize the great benefits, including tuition reimbursement and flexible schedules. Overall, Indeed reviewers recommend Elanco as a top employer in the animal health sector.

Gartner Peer Insights

Gartner Peer Insights ratings reflect Elanco’s performance as a technology provider in animal health. Customers (veterinarians and livestock producers) give a 4.2 out of 5 for product quality, reliability, and innovation. The Elanco Health Hub platform receives high marks for usability and integration with practice management software. Some users request more advanced analytics features.

Trustpilot

On Trustpilot, Elanco has a 4.3-star average based on customer reviews of products like Advantage and Seresto. Pet owners report high efficacy in flea and tick control, with many noting long-lasting protection. Negative reviews are rare but occasionally cite packaging issues or varied results in specific regions. Elanco actively responds to feedback, demonstrating commitment to customer satisfaction.

G2

G2 reviews focus on Elanco’s digital tools. The platform scores 4.0 stars, with users praising FarmIQ for its intuitive interface and predictive analytics. Some suggest adding mobile app functionality. The company’s support team earns consistent praise for responsiveness.

Google Reviews

Google Reviews for the Greenfield headquarters average 4.5 stars. Employees and visitors commend the campus’s cleanliness, modern facilities, and sustainability initiatives. Local community members also appreciate Elanco’s philanthropic events.

LinkedIn Reputation

On LinkedIn, Elanco’s company page has over 300,000 followers, and posts regularly receive high engagement. The company is recognized as a top employer and a leader in the animal health industry. Employees often share testimonials about career growth and collaborative culture. Industry influencers highlight Elanco’s thought leadership in One Health and sustainability.

Why Organizations Choose Elanco Animal Health Incorporated

Organizations across the animal health spectrum select Elanco as a partner for several compelling reasons. First, scientific rigor ensures that products are backed by robust research and regulatory approval, reducing risk for end users. Second, global reach means that customers can rely on consistent supply, technical support, and local expertise in nearly every market. Third, innovation pipeline brings a steady stream of solutions for emerging diseases and production challenges. Fourth, sustainability focus aligns with the corporate social responsibility goals of many buyers, particularly large food companies and retailers that prioritize ethical sourcing. Fifth, customer-centric approach includes training programs, field trials, and responsive service teams that adapt to individual needs. Additionally, Elanco’s financial stability as a publicly traded company with strong cash flow provides confidence in long-term partnerships. The company’s commitment to One Health resonates with organizations that aim to address antimicrobial resistance, zoonotic diseases, and environmental impacts collaboratively. These factors combine to make Elanco a trusted partner for veterinary clinics, agribusinesses, and public health agencies alike.

Official Contact Information

For inquiries and assistance, please reach out to Elanco Animal Health Incorporated using the following contact details:

Address: 2500 Innovation Way, Greenfield, IN 46140, United States
Contact Number: +1 (800) 428-4441
Support Number: +1 (855) 352-6226
Helpdesk Number: +1 (317) 276-9696
Website: www.elanco.com

Official Social Media Presence

Follow Elanco Animal Health Incorporated on the following platforms for the latest news, product updates, and company insights: LinkedIn, Twitter, Facebook, YouTube, and Instagram.

SEO FAQ Section

Elanco Animal Health Incorporated is known for developing innovative pharmaceuticals, vaccines, and feed additives that improve the health and well-being of companion animals and livestock worldwide.

Elanco Animal Health Incorporated is headquartered in Greenfield, Indiana, United States.

Elanco Animal Health Incorporated was founded in 1954 as a division of Eli Lilly and became an independent public company in 2018.

The CEO of Elanco Animal Health Incorporated is Jeff Simmons.

Elanco Animal Health Incorporated generates approximately $4.4 billion in annual revenue.

Elanco Animal Health Incorporated employs over 10,000 people globally.

Elanco Animal Health Incorporated offers a wide range of products including parasiticides, antibiotics, vaccines, feed additives, and diagnostic tools.

Yes, Elanco Animal Health Incorporated is publicly traded on the New York Stock Exchange under the ticker symbol ELAN.

Key brands include Advantage, Seresto, Baytril, Rumensin, Tylan, and Imrestor.

Elanco Animal Health Incorporated supports sustainability through its One Health initiatives, carbon neutrality goals, and partnerships that promote responsible antibiotic use and environmental stewardship.

Elanco Animal Health Incorporated serves veterinary medicine, livestock production, pet retail, agricultural biotechnology, and public health sectors.

Yes, Elanco Animal Health Incorporated provides diagnostic services, telemedicine platforms, and technical training for veterinarians.

Elanco Animal Health Incorporated holds a Glassdoor rating of 4.1 out of 5 stars.

You can apply for jobs at Elanco Animal Health Incorporated through the careers section on their official website.

Elanco Animal Health Incorporated fosters a culture of diversity, inclusion, collaboration, and continuous learning, with a strong focus on mission-driven work.

Yes, Elanco Animal Health Incorporated invests over $400 million annually in R&D to advance animal health innovation.

The 'One Health' approach recognizes the interconnection between human, animal, and environmental health, and Elanco integrates this into its product development and corporate responsibility.

Elanco Animal Health Incorporated has been recognized as one of Forbes’ World’s Best Employers and received Great Place to Work certification in multiple countries.

Elanco Animal Health Incorporated products are available through veterinary clinics, pet stores, online retailers, and agricultural supply distributors.

The official website of Elanco Animal Health Incorporated is www.elanco.com.

For a comprehensive view of corporate and industry resources, including perspectives on digital marketing strategies, readers can explore Elanco Animal Health Incorporated official site alongside external platforms that discuss Paid Guest Posting Sites and related services. Such resources provide additional context for understanding how companies like Elanco leverage digital channels to amplify their brand and reach new audiences.